| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | TX5CYN1KMZ |
| InChI Key | ZADWXFSZEAPBJS-SNVBAGLBSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C12H14N2O2 |
| Molecular Weight | 218.26 |
| AlogP | 1.13 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 68.25 |
| Molecular species | ZWITTERION |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 16.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| ACTIVATOR | mTORC1 activator |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Oxidoreductase
|
110000 | 148900-262750 | - | 19000-37000 | 30.5 | |
|
Enzyme
Transferase
|
- | - | - | - | 7.024-21.3 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | -9.07--0.97 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Melanoma | 2 | D008545 | ClinicalTrials |
| Breast Neoplasms | 2 | D001943 | ClinicalTrials |
| Melanoma | 2 | D008545 | ClinicalTrials |
| Prostatic Neoplasms | 2 | D011471 | ClinicalTrials |
| Ependymoma | 1 | D004806 | ClinicalTrials |
| Gliosarcoma | 1 | D018316 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Glioblastoma | 1 | D005909 | ClinicalTrials |
| Pancreatic Neoplasms | 1 | D010190 | ClinicalTrials |
| Paraganglioma | 1 | D010235 | ClinicalTrials |
| Brain Neoplasms | 1 | D001932 | ClinicalTrials |
| Leukemia, Myeloid, Acute | 1 | D015470 | ClinicalTrials |
| Medulloblastoma | 1 | D008527 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung | 1 | D002289 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 110117-83-4 |
| ChEMBL | CHEMBL571209 |
| DrugBank | DB12827 |
| FDA SRS | TX5CYN1KMZ |
| Guide to Pharmacology | 8226 |
| PubChem | 405012 |
| SureChEMBL | SCHEMBL934800 |
| ZINC | ZINC000000039102 |